Affimed (AFMD) Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors

Go back to Affimed (AFMD) Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors
(NASDAQ: AFMD) Delayed: 9.38 +0.58 (6.59%)
Previous Close $8.80    52 Week High $8.26 
Open $8.62    52 Week Low $1.75 
Day High $9.50    P/E N/A 
Day Low $8.60    EPS $0.00 
Volume 1,254,669